dc.contributor.author |
Rewcastle, Gordon |
en |
dc.contributor.author |
Giddens, Anna |
en |
dc.contributor.author |
Flanagan, Jack |
en |
dc.contributor.author |
Gamage, Swarnalatha |
en |
dc.contributor.author |
Tsang, KY |
en |
dc.contributor.author |
Kendall, Jackie |
en |
dc.contributor.author |
Baguley, Bruce |
en |
dc.contributor.author |
Buchanan, Christina |
en |
dc.contributor.author |
Matthews, DJ |
en |
dc.contributor.author |
O'Farrell, M |
en |
dc.contributor.author |
Jamieson, Stephen |
en |
dc.contributor.author |
Denny, William |
en |
dc.contributor.author |
Shepherd, Peter |
en |
dc.coverage.spatial |
Honolulu, Hawaii, USA |
en |
dc.date.accessioned |
2018-10-10T21:32:58Z |
en |
dc.date.issued |
2015-12-19 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/40544 |
en |
dc.description.abstract |
Phosphoinositide-3-kinase (PI3K) is an important mediator of tumor cell growth, survival and proliferation. In particular, PI3K alpha is important for signaling downstream of receptor tyrosine kinases and is also frequently amplified or mutationally activated in tumors, suggesting that selective inhibitors of this isoform may have therapeutic utility in the treatment of cancer. Downstream of PI3K, the mTOR kinase also plays a critical role in cellular growth and metabolism, and inhibitors of mTOR have demonstrated clinical benefit in several tumor types. We report here the design, discovery and characterization of PWT33597 (VDC-597), a dual inhibitor of PI3K alpha and mTOR, which entered human clinical trials in 2011. Starting with the known pan-Class I PI3-kinase inhibitor ZSTK474, we identified the methanesulfonylpiperazine analogue SN 32538 as a promising lead compound with activity against both PI3K alpha (IC50 = 21 nM) and PI3K delta (IC50 = 18 nM). The addition of a methoxy group at the 4-position of the benzimidazole group led to a more selective inhibitor of PI3K alpha (IC50 = 6 nM versus 41 nM for PI3K delta), although with reduced solubility. A search for more soluble analogues identified SN 32976 as a selective inhibitor of PI3K alpha (IC50 = 28 nM) over both PI3K delta (IC50 = 287 nM) and mTOR (IC50 = 227 nM), with good aqueous solubility. SN 32976 displayed good oral bioavailability and was significantly more active than ZSTK474 against a U87 MG human tumor xenograft model in mice. A search for more metabolically stable analogues subsequently identified PWT33597, which maintained the selectivity for PI3K alpha (IC50 = 26 nM) over PI3K delta (IC50 = 291 nM) but now also displayed activity against mTOR in biochemical assays (IC50 = 21 nM). PWT33597 had good pharmacokinetic properties in multiple preclinical species, was not extensively metabolized in vivo and showed little potential for interaction with cytochrome P450 enzymes. Human clinical trials of PWT33597 were completed in 2012, and it is now undergoing further studies in veterinary cancers (as VDC-597). |
en |
dc.relation.ispartof |
2015 International Chemical Congress of Pacific Basin Societies (Pacifichem) |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Design and Discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR |
en |
dc.type |
Conference Item |
en |
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://ep70.eventpilotadmin.com/web/page.php?page=IntHtml&project=Pachem15&id=2288353 |
en |
pubs.finish-date |
2015-12-20 |
en |
pubs.start-date |
2015-12-15 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.elements-id |
515789 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Molecular Medicine |
en |
pubs.org-id |
Pharmacology |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2016-01-05 |
en |